Skip to main content
Research

Publications: Dr Emma Magavern

Magavern EF, Hitchings A, Bollington L, Wilson K, Hepburn D, Westacott RJ, Sam AH, Caulfield MJ et al. ( 2023 ) . UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment . British Journal of Clinical Pharmacology vol. 90 , ( 2 ) 493 - 503 .
Magavern EF, Durrani F, Raza M, Lerner R, Islam MR, Clinch M, Caulfield MJ ( 2023 ) . British South Asian ancestry participants views of pharmacogenomics clinical implementation and research: a thematic analysis . The Pharmacogenomics Journal vol. 23 , ( 6 ) 185 - 194 .
Magavern EF, Jacobs B, Warren H, Finocchiaro G, Finer S, van Heel DA, Team GHR, Smedley D et al. ( 2023 ) . CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel . JACC Advances vol. 2 , ( 7 )
Magavern EF, Team GHR, Smedley D, Caulfield MJ ( 2023 ) . Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort . iScience vol. 26 , ( 10 )
Magavern EF, Heel DA, Team GHR, Smedley D, Caulfield MJ ( 2023 ) . CYP2C19 loss‐of‐function alleles are not associated with higher prevalence of gastrointestinal bleeds in those who have been prescribed antidepressants: Analysis in a British‐South Asian cohort . British Journal of Clinical Pharmacology vol. 89 , ( 11 ) 3432 - 3438 .
Magavern EF, van Heel DA, Smedley D, Caulfield MJ ( 2023 ) . SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort . The Pharmacogenomics Journal vol. 23 , ( 5 ) 134 - 139 .
Magavern EF, Caulfield MJ ( 2023 ) . Equal access to pharmacogenomics testing: The ethical imperative for population‐wide access in the UK NHS . British Journal of Clinical Pharmacology vol. 89 , ( 5 ) 1701 - 1703 .
Magavern E, Smedley D, Caulfield M ( 2023 ) . Factor V Leiden and oestrogen use in the context of multiple common chronic medical conditions: Analysis in the Genes & Health British-South Asian Cohort . BRITISH JOURNAL OF PHARMACOLOGY . vol. 180 , 368 - 371 .
Magavern E, van Heel D, Smedley D, Caulfield M ( 2023 ) . Precision prescribing would not reduce gastrointestinal bleeds associated with CYP2C19 metabolized antidepressants:: Analysis in a British-South Asian cohort . BRITISH JOURNAL OF PHARMACOLOGY . vol. 180 , 365 - 368 .
( 2022 ) . Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy . European Heart Journal - Cardiovascular Pharmacotherapy vol. 9 , ( 1 ) 116 - 116 .
Adeyeye E, Maniero C, Magavern EF, Ferner RE, McGettigan P ( 2022 ) . Prescribing direct‐acting oral anticoagulants – Mind the evidence gap . British Journal of Clinical Pharmacology vol. 88 , ( 11 ) 4724 - 4731 .
Turner RM, Magavern EF, Pirmohamed M ( 2022 ) . Pharmacogenomics: Relevance and opportunities for clinical pharmacology . British Journal of Clinical Pharmacology vol. 88 , ( 9 ) 3943 - 3946 .
Finocchiaro G, Magavern EF, Georgioupoulos G, Maurizi N, Sinagra G, Carr-White G, Pantazis A, Olivotto I ( 2022 ) . Sudden cardiac death in cardiomyopathies: acting upon “acceptable” risk in the personalized medicine era . Heart Failure Reviews vol. 27 , ( 5 ) 1749 - 1759 .
Magavern EF, Piasecki J, Cohen A, Cremers S ( 2021 ) . Ethics in clinical pharmacology: Facilitating public trust . British Journal of Clinical Pharmacology vol. 88 , ( 1 ) 5 - 6 .
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN et al. ( 2021 ) . Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy . European Heart Journal - Cardiovascular Pharmacotherapy vol. 8 , ( 1 ) 100 - 103 .
Magavern EF, Gurdasani D, Ng FL, Lee SS ( 2021 ) . Health equality, race and pharmacogenomics . British Journal of Clinical Pharmacology vol. 88 , ( 1 ) 27 - 33 .
Magavern EF, Daly AK, Gilchrist A, Hughes DA ( 2021 ) . Pharmacogenomics spotlight commentary: From the United Kingdom to global populations . British Journal of Clinical Pharmacology vol. 87 , ( 12 ) 4546 - 4548 .
Magavern EF, Cremers S ( 2021 ) . Introduction to clinical pharmacology at large . British Journal of Clinical Pharmacology vol. 87 , ( 8 ) 3026 - 3027 .
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN et al. ( 2021 ) . The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy . European Heart Journal - Cardiovascular Pharmacotherapy vol. 8 , ( 1 ) 85 - 99 .
Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, Abdelfattah M, Abdul B et al. ( 2021 ) . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 397 , ( 10274 ) 605 - 612 .
Magavern EF, Kaski JC, Turner RM, Janmohamed A, Borry P, Pirmohamed M ( 2021 ) . The Interface of Therapeutics and Genomics in Cardiovascular Medicine . Cardiovascular Drugs and Therapy vol. 35 , ( 3 ) 663 - 676 .
Magavern EF, Warren HR, Ng FL, Cabrera CP, Munroe PB, Caulfield MJ ( 2021 ) . An Academic Clinician’s Road Map to Hypertension Genomics . Hypertension vol. 77 , ( 2 ) 284 - 295 .
Burrai F, Magavern EF, Micheluzzi V, Magnaghi C, Apuzzo L, Brioni E ( 2020 ) . Effectiveness of Music to Improve Anxiety in Hemodialysis Patients . Holistic Nursing Practice vol. 34 , ( 6 ) 324 - 333 .
Magavern E, Khong TK ( 2020 ) . Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes . Drug and Therapeutics Bulletin vol. 59 , ( 2 ) 22 - 23 .
Burrai F, Mettifogo M, Micheluzzi V, Ferreira FE, Pinna L, Magavern EF ( 2020 ) . Narrative-Based Practice . Holistic Nursing Practice vol. 34 , ( 5 ) 306 - 313 .